FemLUNA

About EndoCyclic Therapeutics

EndoCyclic Therapeutics is pioneering a novel class of precision peptide therapeutics and diagnostics based on a platform technology that enables selective uptake and pH-sensitive activation within diseased cells. The company's pipeline is focused on high-need areas, including endometriosis, where it is advancing both a potential disease-modifying therapeutic (ENDO-205) and a non-invasive diagnostic (FemLUNA), as well as oncology programs. With an IND cleared for its lead candidate, EndoCyclic is positioned to address significant unmet medical needs with a targeted, non-hormonal approach that aims to avoid systemic toxicity.

Therapeutic Areas

Other Endometriosis Diagnosis Drugs